Alfredo Dias Oliveira-Filho

Dr. Alfredo Dias Oliveira-Filho

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TSTâmara Natasha Gonzaga de Andrade Santos
Tâmara Natasha Gonzaga de Andrade Santos
GMGivalda Mendonça da Cruz Macieira
Givalda Mendonça da Cruz Macieira
BABárbara Manuella Cardoso Sodré Alves
Bárbara Manuella Cardoso Sodré Alves
TOThelma Onozato
Thelma Onozato
GCGeovanna Cunha Cardoso
Geovanna Cunha Cardoso
AOAlfredo Dias Oliveira-Filho
Alfredo Dias Oliveira-Filho
This review aims to determine the prevalence of clinically manifested drug-drug interactions (DDIs) in hospitalized patients. PubMed, Scopus, Embase, Web of Science, and Lilacs databases were used to identify articles published before June 2019 that met specific inclusion criteria. The search strategy was developed using both controlled and uncontrolled vocabulary related to the following domains: “drug interactions,” “clinically relevant,” and “hospital.” In this review, we discuss original observational studies that detected DDIs in the hospital setting, studies that provided enough data to allow us to calculate the prevalence of clinically manifested DDIs, and studies that described the drugs prescribed or provided DDI adverse reaction reports, published in either English, Portuguese, or Spanish. From the initial 5,999 articles identified, 10 met the inclusion criteria. The pooled prevalence of clinically manifested DDIs was 9.2% (CI 95% 4.0–19.7). The mean number of medications per patient reported in six studies ranged from 4.0 to 9.0, with an overall average of 5.47 ± 1.77 drugs per patient. The quality of the included studies was moderate. The main methods used to identify clinically manifested DDIs were evaluating medical records and ward visits (n = 7). Micromedex® (27.7%) and Lexi-Comp® (27.7%) online reference databases were commonly used to detect DDIs and none of the studies evaluated used more than one database for this purpose. This systematic review showed that, despite the significant prevalence of potential DDIs reported in the literature, less than one in ten patients were exposed to a clinically manifested drug interaction. The use of causality tools to identify clinically manifested DDIs as well as clinical adoption of DDI lists based on actual adverse outcomes that can be identified through the implementation of real DDI notification systems is recommended to reduce the incidence of alert fatigue, enhance decision-making for DDI prevention or resolution, and, consequently, contribute to patient safety.

24 March 2020 in Journal of Patient Safety
Verified
Journal Article
Closed access
BABárbara Manuella Cardoso Msc Sodré Alves
Bárbara Manuella Cardoso Msc Sodré Alves
TATâmara Natasha Gonzaga PhD Student de Andrade
Tâmara Natasha Gonzaga PhD Student de Andrade
SSSabrina PhD Student Cerqueira Santos
Sabrina PhD Student Cerqueira Santos
AGAline Santana PhD Student Goes
Aline Santana PhD Student Goes
ASAdriano da Silva PhD Student Santos
Adriano da Silva PhD Student Santos
AOAlfredo Dias Oliveira-Filho
Alfredo Dias Oliveira-Filho
Objective: The aim of the study was to determine the prevalence and main types of harm caused by high-alert medication after medication errors (MEs) in hospitals. Method: A literature systematic review was conducted on PubMed, Scopus, Web of Science, and Lilacs. Eligible studies published until June 2017 were included. Result: Of 6244 studies identified through searching four electronic databases, five studies meeting the selection criteria of this study were analyzed. There was wide variation in the overall prevalence of harm due to MEs involving HAM, from 3.8% to 100%, whereas the pooled prevalence was 16.3%. Overall, 0.01% of harm caused by MEs involving HAM resulted in death. The severity of errors ranged from 0.1% to 19.2% for moderate errors, 0.2% to 15.4% for serious errors, and 1.9% lethal to the patients. The highest prevalences of harm occurred after errors involving potassium chloride 15%, insulin, and epoprostenol. The lowest prevalence of harm was related to errors of anticoagulants administration. The methodological heterogeneity limited direct comparisons among the studies. Conclusions: Of the 15 drugs on the list of Institute for Safe Medication Practices HAMs in the United States and Brazil, nine did not present scientific evidence of the potential for harm. In general, few studies, characterized by methodological and conceptual heterogeneity, were performed to determine the harm prevalence resulting from errors involving these drugs.

1 March 2014 in International Journal of Cardiology
Verified
Journal Article
Closed access
AOAlfredo Dias Oliveira-Filho
Alfredo Dias Oliveira-Filho
FCFrancisco A. Costa
Francisco A. Costa
SNSabrina Joany Felizardo Neves
Sabrina Joany Felizardo Neves
DJDivaldo Pereira de Lyra Junior
Divaldo Pereira de Lyra Junior
DMDonald Morisky
Donald Morisky

11 April 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SSSimony M. Soares
Simony M. Soares
MDMirela Q. de Almeida Diniz
Mirela Q. de Almeida Diniz
DDDilcy Morgana B. M. C. Davino
Dilcy Morgana B. M. C. Davino
FAFernanda B. Albieri
Fernanda B. Albieri
ASAdriano S. Santos
Adriano S. Santos
AOAlfredo Dias Oliveira-Filho
Alfredo Dias Oliveira-Filho
Background: Self-reported adherence scales are widely used in research and practice because they are low in cost and easy to apply. A free version in Brazilian-Portuguese of the Simplified Medication Adherence Questionnaire (SMAQ) can be a useful alternative for determining the adherent behavior of hypertensive patients.Purpose: To translate and evaluate the psychometric properties of the Brazilian-Portuguese version of the SMAQ therapeutic adherence scale for patients with arterial hypertension.Patients and methods: A multicenter, cross-sectional study was conducted in five outpatient units in Maceió-AL and Aracaju-SE between January and July 2019. A total of 117 patients aged over 18 years using antihypertensive drugs were recruited. The cross-cultural adaptation followed international methodological recommendations. Internal consistency (Cronbach’s alpha) was tested as a reliability parameter. Criterion and construct validity were verified by concurrent validation, exploratory factor analysis (EFA), and validation by known groups.Results: The participants had a mean age of 56.6 years (SD = 10.7 years); most were female (72.6%). The mean number of antihypertensives prescribed per patient was 1.87 (SD = 0.87). There were 79.5% (n = 86) of patients considered non-adherent. Internal consistency was satisfactory (Cronbach’s alpha = 0.63). A satisfactory correlation coefficient was verified with the Morisky–Green–Levine test as an external criterion (r = 0.56, p < 0.001). The scale’s sensitivity measured through known group validity was 75.3%, specificity 29.5%, positive predictive value 63.9%, and negative predictive value 41.9%. We identified two factors of the instrument’s construct from EFA: specific medication-taking behaviors and barriers to adherence. The initial KMO measure of sampling adequacy was 0.691, and Bartlett’s test of sphericity was significant (χ2 = 118.342, p < 0.001).Conclusion: The Brazilian-Portuguese version of the SMAQ scale proved valid and reliable for determining adherence to the pharmacotherapy in hypertensive patients. It showed more ability to detect non-adherent patients but with low specificity, possibly influenced by high social desirability.

21 February 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CSCarla Maria Lima Silva
Carla Maria Lima Silva
LMLuiz Eduardo Oliveira Matos
Luiz Eduardo Oliveira Matos
ASAndressa Ribeiro Sassaqui
Andressa Ribeiro Sassaqui
AOAlfredo Dias Oliveira-Filho
Alfredo Dias Oliveira-Filho
CRChiara Erminia da Rocha
Chiara Erminia da Rocha
GBGiselle de Carvalho Brito
Giselle de Carvalho Brito
Trans people face numerous barriers to access and permanence in health services, which makes it difficult, among other things, to know about their quality of life and satisfaction with health services related to these users. Thus, the objective was to describle the quality of life and satisfaction with pharmacotherapeutic follow-up in transgender people. A cross-sectional, descriptive, and quantitative study was conducted between January and September 2022 at a specialized outpatient clinic for transgender individuals. The following aspects were describle: sociodemographic and medication profiles; quality of Life, which was measured using the WHOQOL-BREF questionnaire; and levels of satisfaction with Pharmacotherapeutic Monitoring, assessed through the Pharmacy Services Satisfaction Questionnaire (QSSF). Descriptive analyses employed measures of central tendency, absolute and relative frequencies, while inferential analyses used the Student’s t test. A total of 101 transgender individuals participated in the study, with a mean age of 25 years, the majority being single (79.2%/80), having more than 11 years of education (47.5%/n = 48), and comprising 48.5% (n = 49) transgender women. Hormone use was reported by 59.4% (n = 60) of the participants, with 18.3% (n = 11) of self-medication. Testosterone cypionate was the most common hormone used by transgender men (84%), while cyproterone acetate and estradiol represented 60.4% of hormone use among transgender women. Additionally, 36 transgender individuals were taking other drugs (n = 60), mainly antidepressives (28%). The WHOQOL-BREF showed higher scores in the domains of self-rated Quality of Life, and physical, and psychological well-being among transgender women compared to transgender men, but without statistical differences. Income revealed a statistically significant association with psychological domains and overall quality of life. The results of the QSSF indicated that the overall mean and average scores per question were higher than 4, suggesting that 100% of the sample was satisfied with the provided service. No statistically significant differences were observed in the Quality of Life between transgender men and women, but income was associated with the psychological domain and overall Quality of Life. All participants reported satisfaction with the Pharmacotherapeutic Monitoring service; however, there is a need to expand service offerings, such as medication dispensing.

21 April 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
FAFábio Jorge Ramalho de Amorim
Fábio Jorge Ramalho de Amorim
FVFernanda Valença-Feitosa
Fernanda Valença-Feitosa
MRMarcos Cardoso Rios
Marcos Cardoso Rios
CSCarlos Adriano Santos Souza
Carlos Adriano Santos Souza
IBIzadora Menezes da Cunha Barros
Izadora Menezes da Cunha Barros
DLDivaldo Pereira de Lyra-Júnior
Divaldo Pereira de Lyra-Júnior
Background: The clinical activities developed by pharmacists in a hospital environment can improve health outcomes and generate savings for hospitals. However, to determine whether pharmaceutical interventions are cost effective, it is essential to define a method according to which cost-effectiveness is intended to be measured. In addition, the quality of economic assessments and the amount of information present in systematic reviews in the literature make it difficult to analyze the effects of this intervention. Objective: This paper aims to provide an overview of systematic reviews on the pharmacoeconomic impact of the performance of pharmaceutical care in hospitals. Methods: A systematic search of the Cochrane Library databases, PubMed or MEDLINE, LILACS, Scopus, Web of Science, Google Scholar, and Open Thesis will be performed using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. The search will involve the use of keywords determined using the Medical Subject Headings database to define the search terms and include the following terms: “pharmacoeconomics,” “pharmaceutical care,” and “hospital.” The study designs to be included will be systematic reviews of good quality. Studies will be included that address pharmacoeconomics; studies that evaluated pharmaceutical care in hospitals; and studies published in Portuguese, English, or Spanish. The primary outcome sought in the systematic reviews will be the cost ratio in monetary units and the outcomes in monetary or natural units. The secondary economic outcomes considered will be determined based on factors associated with the drugs and translated into benefit, efficacy, or utility. Results: It is intended to start this overview in January 2023. Thus far, only previous searches have been carried out to contextualize the theme and build the protocol. Conclusions: This overview will determine the pharmacoeconomic impact of pharmaceutical care interventions in the hospital environment. In addition, this study will point out which clinical outcomes in natural units are impacted by the performance of pharmaceutical care and the strengths and limitations of each approach. It will also identify gaps in the literature and areas for future work. Trial Registration: PROSPERO CRD42019140665; https://tinyurl.com/bddwnz43